These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 27657443)
1. Approach for Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue Uptake. Schneider EL; Hearn BR; Pfaff SJ; Fontaine SD; Reid R; Ashley GW; Grabulovski S; Strassberger V; Vogt L; Jung T; Santi DV Bioconjug Chem; 2016 Oct; 27(10):2534-2539. PubMed ID: 27657443 [TBL] [Abstract][Full Text] [Related]
2. Primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system. Hearn BR; Fontaine SD; Pfaff SJ; Schneider EL; Henise J; Ashley GW; Santi DV J Control Release; 2018 May; 278():74-79. PubMed ID: 29577950 [TBL] [Abstract][Full Text] [Related]
3. Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide. Schneider EL; Henise J; Reid R; Ashley GW; Santi DV Bioconjug Chem; 2016 May; 27(5):1210-5. PubMed ID: 26930186 [TBL] [Abstract][Full Text] [Related]
4. Hydrogel drug delivery system with predictable and tunable drug release and degradation rates. Ashley GW; Henise J; Reid R; Santi DV Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2318-23. PubMed ID: 23345437 [TBL] [Abstract][Full Text] [Related]
5. Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology. Schneider EL; Ashley GW; Dillen L; Stoops B; Austin NE; Malcolm BA; Santi DV Eur J Pharm Biopharm; 2015 Jun; 93():254-9. PubMed ID: 25900863 [TBL] [Abstract][Full Text] [Related]
6. A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist. Schneider EL; Hearn BR; Pfaff SJ; Reid R; Parkes DG; Vrang N; Ashley GW; Santi DV ACS Chem Biol; 2017 Aug; 12(8):2107-2116. PubMed ID: 28605180 [TBL] [Abstract][Full Text] [Related]
8. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Santi DV; Schneider EL; Reid R; Robinson L; Ashley GW Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6211-6. PubMed ID: 22474378 [TBL] [Abstract][Full Text] [Related]
9. A Controlled Release System for Long-Acting Intravitreal Delivery of Small Molecules. Machinaga N; Ashley GW; Reid R; Yamasaki A; Tanaka K; Nakamura K; Yabe Y; Yoshigae Y; Santi DV Transl Vis Sci Technol; 2018 Jul; 7(4):21. PubMed ID: 30174998 [TBL] [Abstract][Full Text] [Related]
10. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. Albrecht H; Denardo GL; Denardo SJ J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921 [TBL] [Abstract][Full Text] [Related]
11. Biodegradable tetra-PEG hydrogels as carriers for a releasable drug delivery system. Henise J; Hearn BR; Ashley GW; Santi DV Bioconjug Chem; 2015 Feb; 26(2):270-8. PubMed ID: 25584814 [TBL] [Abstract][Full Text] [Related]
12. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Chan BS; Buckley NA Clin Toxicol (Phila); 2014; 52(8):824-36. PubMed ID: 25089630 [TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life. Asano R; Koyama N; Hagiwara Y; Masakari Y; Orimo R; Arai K; Ogata H; Furumoto S; Umetsu M; Kumagai I FEBS Open Bio; 2016 Jun; 6(6):594-602. PubMed ID: 27419062 [TBL] [Abstract][Full Text] [Related]
14. GlycoTAIL and FlexiTAIL as Half-Life Extension Modules for Recombinant Antibody Fragments. Seifert O; Kontermann RE Molecules; 2022 May; 27(10):. PubMed ID: 35630749 [TBL] [Abstract][Full Text] [Related]
15. New strategy for the extension of the serum half-life of antibody fragments. Trüssel S; Dumelin C; Frey K; Villa A; Buller F; Neri D Bioconjug Chem; 2009 Dec; 20(12):2286-92. PubMed ID: 19916518 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377 [TBL] [Abstract][Full Text] [Related]
18. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Desai SA; Wang X; Noronha EJ; Kageshita T; Ferrone S Cancer Res; 1998 Jun; 58(11):2417-25. PubMed ID: 9622083 [TBL] [Abstract][Full Text] [Related]
19. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Albrecht H; Denardo GL; Denardo SJ Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]